Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized with SARS-CoV-2 pneumonia confirmed by RT-PCR or serology (IgA);~* PaO2/FiO2 \< 300 (not fully explained by heart failure or volume overload) or SpO2 \< 90% on room air.~Exclusion Criteria:~* Symptom onset \> 14 days;~* Neutrophil count \< 1,000/mm3;~* Platelets \< 50,000/mm3;~* ICU care at enrollment;~* On invasive mechanical ventilation at enrollment;~* Current use of experimental therapy for COVID-19 (except: azithromycin or corticosteroids)~* Uncontrolled arterial hypertension;~* Current or previous use of systemic immunosuppressive therapy in the last 30 days;~* Pregnancy or lactation;~* Estimated creatinine clearance \< 30 mL/min or receiving CRRT or intermittent hemodialysis;~* Allergy to ruxolitinib;~* Active tuberculosis;~* HIV seropositivity;~* Prior history of progressive multifocal leukoencephalopathy;~* Use of any JAK inhibitor in the last 30 days before study enrollment;~* Not qualifying according to investigators' perception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Group - ruxolitinib (Type: EXPERIMENTAL): Ruxolitinib 5 mg PO b.i.d. for 14 days
- Placebo Group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).